Net Income (Loss) Attributable to Parent in USD of GALECTIN THERAPEUTICS INC from Q2 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
GALECTIN THERAPEUTICS INC quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from Q2 2010 to Q3 2025.
  • GALECTIN THERAPEUTICS INC Net Income (Loss) Attributable to Parent for the quarter ending 30 Sep 2025 was -$8,184,000.000, a 27.1% increase year-over-year.
  • GALECTIN THERAPEUTICS INC Net Income (Loss) Attributable to Parent for the twelve months ending 30 Sep 2025 was -$37,303,000.000, a 17.2% increase year-over-year.
  • GALECTIN THERAPEUTICS INC annual Net Income (Loss) Attributable to Parent for 2024 was -$47,047,000.000, a 14.6% decline from 2023.
  • GALECTIN THERAPEUTICS INC annual Net Income (Loss) Attributable to Parent for 2023 was -$41,066,000.000, a 5.91% decline from 2022.
  • GALECTIN THERAPEUTICS INC annual Net Income (Loss) Attributable to Parent for 2022 was -$38,776,000.000, a 27% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

GALECTIN THERAPEUTICS INC Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$37,303,000 -$8,184,000 +$3,036,000 +27.1% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025
Q2 2025 -$40,339,000 -$7,521,000 +$4,850,000 +39.2% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025
Q1 2025 -$45,189,000 -$9,631,000 +$1,858,000 +16.2% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025
Q4 2024 -$47,047,000 -$11,967,000 -$1,970,000 -19.7% 01 Oct 2024 31 Dec 2024 10-K 31 Mar 2025
Q3 2024 -$45,077,000 -$11,220,000 -$792,000 -7.6% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025
Q2 2024 -$44,285,000 -$12,371,000 -$3,257,000 -35.7% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025
Q1 2024 -$41,028,000 -$11,489,000 +$38,000 +0.33% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025
Q4 2023 -$41,066,000 -$9,997,000 +$637,000 +6% 01 Oct 2023 31 Dec 2023 10-K 31 Mar 2025
Q3 2023 -$41,703,000 -$10,428,000 -$1,831,000 -21.3% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024
Q2 2023 -$39,872,000 -$9,114,000 +$499,000 +5.2% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024
Q1 2023 -$40,371,000 -$11,527,000 -$1,595,000 -16.1% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024
Q4 2022 -$38,776,000 -$10,634,000 -$3,414,000 -47.3% 01 Oct 2022 31 Dec 2022 10-K 29 Mar 2024
Q3 2022 -$35,362,000 -$8,597,000 -$77,000 -0.9% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023
Q2 2022 -$35,285,000 -$9,613,000 -$1,164,000 -13.8% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023
Q1 2022 -$34,121,000 -$9,932,000 -$3,594,000 -56.7% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023
Q4 2021 -$30,527,000 -$7,220,000 +$632,000 +8% 01 Oct 2021 31 Dec 2021 10-K 30 Mar 2023
Q3 2021 -$31,159,000 -$8,520,000 -$2,577,000 -43.4% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022
Q2 2021 -$28,582,000 -$8,449,000 -$2,335,000 -38.2% 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022
Q1 2021 -$26,247,000 -$6,338,000 -$2,782,000 -78.2% 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022
Q4 2020 -$23,465,000 -$7,852,000 -$2,715,000 -52.9% 01 Oct 2020 31 Dec 2020 10-K 31 Mar 2022
Q3 2020 -$20,750,000 -$5,943,000 -$3,159,000 -1.1% 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021
Q2 2020 -$17,591,000 -$6,114,000 -$3,116,000 -1% 01 Apr 2020 30 Jun 2020 10-Q 16 Aug 2021
Q1 2020 -$14,475,000 -$3,556,000 -$1,181,000 -49.7% 01 Jan 2020 31 Mar 2020 10-Q 17 May 2021
Q4 2019 -$13,294,000 -$5,137,000 -$2,087,000 -68.4% 01 Oct 2019 31 Dec 2019 10-K 31 Mar 2021
Q3 2019 -$11,207,000 -$2,784,000 -$32,000 -1.2% 01 Jul 2019 30 Sep 2019 10-Q 09 Nov 2020
Q2 2019 -$11,175,000 -$2,998,000 +$842,000 +21.9% 01 Apr 2019 30 Jun 2019 10-Q 10 Aug 2020
Q1 2019 -$12,017,000 -$2,375,000 +$1,883,000 +44.2% 01 Jan 2019 31 Mar 2019 10-Q 11 May 2020
Q4 2018 -$13,900,000 -$3,050,000 -$668,000 -28% 01 Oct 2018 31 Dec 2018 10-K 16 Mar 2020
Q3 2018 -$13,232,000 -$2,752,000 +$1,656,000 +37.6% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019
Q2 2018 -$14,888,000 -$3,840,000 +$668,000 +14.8% 01 Apr 2018 30 Jun 2018 10-Q 09 Aug 2019
Q1 2018 -$15,556,000 -$4,258,000 +$679,000 +13.8% 01 Jan 2018 31 Mar 2018 10-Q 10 May 2019
Q4 2017 -$16,235,000 -$2,382,000 +$2,209,000 +48.1% 01 Oct 2017 31 Dec 2017 10-K 06 Mar 2019
Q3 2017 -$18,444,000 -$4,408,000 +$118,000 +2.6% 01 Jul 2017 30 Sep 2017 10-Q 13 Nov 2018
Q2 2017 -$18,562,000 -$4,508,000 +$1,011,000 +18.3% 01 Apr 2017 30 Jun 2017 10-Q 14 Aug 2018
Q1 2017 -$19,573,000 -$4,937,000 +$1,863,000 +27.4% 01 Jan 2017 31 Mar 2017 10-Q 11 May 2018
Q4 2016 -$21,436,000 -$4,591,000 +$80,000 +1.7% 01 Oct 2016 31 Dec 2016 10-K 29 Mar 2018
Q3 2016 -$21,516,000 -$4,526,000 +$1,361,000 +23.1% 01 Jul 2016 30 Sep 2016 10-Q 07 Nov 2017
Q2 2016 -$22,877,000 -$5,519,000 -$876,000 -18.9% 01 Apr 2016 30 Jun 2016 10-Q 14 Aug 2017
Q1 2016 -$22,001,000 -$6,800,000 -$1,974,000 -40.9% 01 Jan 2016 31 Mar 2016 10-Q 15 May 2017
Q4 2015 -$20,027,000 -$4,671,000 -$940,000 -25.2% 01 Oct 2015 31 Dec 2015 10-K 15 Mar 2016
Q3 2015 -$19,087,000 -$5,887,000 -$2,369,000 -67.3% 01 Jul 2015 30 Sep 2015 10-Q 08 Nov 2016
Q2 2015 -$16,718,000 -$4,643,000 -$1,214,000 -35.4% 01 Apr 2015 30 Jun 2015 10-Q 09 Aug 2016
Q1 2015 -$15,504,000 -$4,826,000 +$284,000 +5.6% 01 Jan 2015 31 Mar 2015 10-Q 10 May 2016
Q4 2014 -$15,788,000 -$3,731,000 -$932,000 -33.3% 01 Oct 2014 31 Dec 2014 10-K 15 Mar 2016
Q3 2014 -$14,856,000 -$3,518,000 +$24,000 +0.68% 01 Jul 2014 30 Sep 2014 10-K 15 Mar 2016
Q2 2014 -$14,880,000 -$3,429,000 -$885,000 -34.8% 01 Apr 2014 30 Jun 2014 10-K 15 Mar 2016
Q1 2014 -$13,995,000 -$5,110,000 -$1,907,000 -59.5% 01 Jan 2014 31 Mar 2014 10-K 15 Mar 2016
Q4 2013 -$12,088,000 -$2,799,000 -$423,000 -17.8% 01 Oct 2013 31 Dec 2013 10-K 18 Mar 2015
Q3 2013 -$11,665,000 -$3,542,000 -$853,000 -31.7% 01 Jul 2013 30 Sep 2013 10-K 18 Mar 2015
Q2 2013 -$10,812,000 -$2,544,000 +$116,000 +4.4% 01 Apr 2013 30 Jun 2013 10-K 18 Mar 2015
Q1 2013 -$10,928,000 -$3,203,000 -$1,253,000 -64.3% 01 Jan 2013 31 Mar 2013 10-K 18 Mar 2015
Q4 2012 -$9,675,000 -$2,376,000 +$992,000 +29.5% 01 Oct 2012 31 Dec 2012 10-K 18 Mar 2015
Q3 2012 -$10,667,000 -$2,689,000 -$661,000 -32.6% 01 Jul 2012 30 Sep 2012 10-Q 12 Nov 2013
Q2 2012 -$10,006,000 -$2,660,000 +$467,000 +14.9% 29 Mar 2012 30 Jun 2012 10-Q 14 Aug 2013
Q1 2012 -$10,473,000 -$1,950,000 +$442,000 +18.5% 01 Jan 2012 31 Mar 2012 10-Q 10 May 2013
Q4 2011 -$10,915,000 -$3,368,000 01 Oct 2011 31 Dec 2011 10-K 29 Mar 2013
Q3 2011 -$2,028,000 -$919,000 -82.9% 01 Jul 2011 30 Sep 2011 10-Q 09 Nov 2012
Q2 2011 -$3,127,000 -$1,473,000 -89.1% 01 Apr 2011 30 Jun 2011 10-Q 10 Aug 2012
Q1 2011 -$2,392,000 01 Jan 2011 31 Mar 2011 10-Q 11 May 2012
Q3 2010 -$1,109,000 01 Jul 2010 30 Sep 2010 10-Q 10 Nov 2011
Q2 2010 -$1,654,000 01 Apr 2010 30 Jun 2010 10-Q 12 Aug 2011

GALECTIN THERAPEUTICS INC Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$47,047,000 -$5,981,000 -14.6% 01 Jan 2024 31 Dec 2024 10-K 31 Mar 2025
2023 -$41,066,000 -$2,290,000 -5.9% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025
2022 -$38,776,000 -$8,249,000 -27% 01 Jan 2022 31 Dec 2022 10-K 29 Mar 2024
2021 -$30,527,000 -$7,062,000 -30.1% 01 Jan 2021 31 Dec 2021 10-K 30 Mar 2023
2020 -$23,465,000 -$10,171,000 -76.5% 01 Jan 2020 31 Dec 2020 10-K 31 Mar 2022
2019 -$13,294,000 +$606,000 +4.4% 01 Jan 2019 31 Dec 2019 10-K 31 Mar 2021
2018 -$13,900,000 +$2,335,000 +14.4% 01 Jan 2018 31 Dec 2018 10-K 16 Mar 2020
2017 -$16,235,000 +$5,201,000 +24.3% 01 Jan 2017 31 Dec 2017 10-K 06 Mar 2019
2016 -$21,436,000 -$1,409,000 -7% 01 Jan 2016 31 Dec 2016 10-K 29 Mar 2018
2015 -$20,027,000 -$4,239,000 -26.8% 01 Jan 2015 31 Dec 2015 10-K 28 Mar 2017
2014 -$15,788,000 -$3,700,000 -30.6% 01 Jan 2014 31 Dec 2014 10-K 15 Mar 2016
2013 -$12,088,000 -$2,413,000 -24.9% 01 Jan 2013 31 Dec 2013 10-K 15 Mar 2016
2012 -$9,675,000 +$1,240,000 +11.4% 01 Jan 2012 31 Dec 2012 10-K 18 Mar 2015
2011 -$10,915,000 -$5,286,000 -93.9% 01 Jan 2011 31 Dec 2011 10-K 29 Mar 2013
2010 -$5,629,000 01 Jan 2010 31 Dec 2010 10-K 30 Mar 2012
* An asterisk sign (*) next to the value indicates that the value is likely invalid.